MedTrace Logo

Efficacy of a Brown Seaweed Powder for Glycemic Control

NCT02853916 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-10-26

No results posted yet for this study

Summary

The objectives of this trial are to confirm efficacy in human of a brown seaweed powder and explore dose-response relationship by comparing two different doses.

The primary endpoint is incremental area under the curve (iAUC, mmol\*min/L) for blood glucose.

Conditions

  • Blood Glucose

Interventions

DIETARY_SUPPLEMENT

500 mg InSea2®

DIETARY_SUPPLEMENT

250 mg InSea2®

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • innoVactiv Inc.

    collaborator INDUSTRY

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Peter Jones, PhD · University of Manitoba

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-04-30
Completion
2017-10-25

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02853916 on ClinicalTrials.gov